{{Rsnum
|rsid=9322817
|Gene=HACE1
|Chromosome=6
|position=104784358
|Orientation=plus
|GMAF=0.3907
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=HACE1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 35.4 | 48.7 | 15.9
| HCB | 62.0 | 30.7 | 7.3
| JPT | 54.9 | 43.4 | 1.8
| YRI | 13.6 | 46.9 | 39.5
| ASW | 24.6 | 40.4 | 35.1
| CHB | 62.0 | 30.7 | 7.3
| CHD | 53.3 | 39.3 | 7.5
| GIH | 43.6 | 51.5 | 5.0
| LWK | 10.9 | 48.2 | 40.9
| MEX | 50.0 | 39.7 | 10.3
| MKK | 21.2 | 46.8 | 32.1
| TSI | 40.2 | 51.0 | 8.8
| HapMapRevision=28
}}{{GWAS Summary
|SNP=rs9322817
|PubMedID=17903292
|Condition=Thyroid stimulating hormone
|Gene=HACE1
|Risk Allele=
|pValue=7.00E-006
|OR=NA
|95CI=
|OA=1
}}

{{PharmGKB
|RSID=rs9322817
|Name_s=
|Gene_s=HACE1
|Feature=
|Evidence=PubMed ID:17903292; Web Resource:http://www.genome.gov/gwastudies/
|Annotation=GWAS results: A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study (Initial Sample Size: 810-1,010 individuals depending on measure (Framingham); Replication Sample Size: NR). This variant is associated with Thyroid stimulating hormone level.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Non-Curated
|PharmGKB Accession ID=PA162356363
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs9322817
|overall_frequency_n=1290
|overall_frequency_d=3234
|overall_frequency=0.398887
|n_genomes=33
|n_genomes_annotated=0
|n_haplomes=45
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}